Viridian Therapeutics Inc VRDN Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$19.05 down $0.51, 2.61% at close Oct 16
Last close · Previous close $19.56
- Market cap
- At the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$3.39Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$19.05down $0.51, 2.61%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$19.56Oct 15
- Volume2.17MOct 15 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.20MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $13.18 to $34.29; now $19.05
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
VRDN beat the S&P 500 in 1 of 7 periods.
| Period | VRDN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VRDN: down 15.1% S&P 500: up 1.5% | VRDN trailed the S&P 500 by 16.6 percentage points Trailed |
| 3M | VRDN: up 5.7% S&P 500: up 1.9% | VRDN beat the S&P 500 by 3.8 percentage points Beat |
| YTD | VRDN: down 38.8% S&P 500: up 12.8% | VRDN trailed the S&P 500 by 51.6 percentage points Trailed |
| 1Y | VRDN: down 17.2% S&P 500: up 16.8% | VRDN trailed the S&P 500 by 34.0 percentage points Trailed |
| Long term | ||
| 3Y | VRDN: up 60.4% S&P 500: up 81.5% +17.0% vs +22.0% a year | VRDN trailed the S&P 500 by 21.1 percentage points Trailed |
| 5Y | VRDN: up 11.6% S&P 500: up 83.1% +2.2% vs +12.9% a year | VRDN trailed the S&P 500 by 71.5 percentage points Trailed |
| 10Y | VRDN: down 82.0% S&P 500: up 319.6% −15.8% vs +15.4% a year | VRDN trailed the S&P 500 by 401.6 percentage points Trailed |
$10,000 invested in VRDN 10 years ago (Oct 14, 2016) would be worth about $1,800 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
VRDN beat the S&P 500 in 1 of 7 periods.
| Period | VRDN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VRDN: down 15.1% S&P 500: up 1.2% | VRDN trailed the S&P 500 by 16.3 percentage points Trailed |
| 3M | VRDN: up 5.7% S&P 500: up 1.7% | VRDN beat the S&P 500 by 4.0 percentage points Beat |
| YTD | VRDN: down 38.8% S&P 500: up 11.9% | VRDN trailed the S&P 500 by 50.7 percentage points Trailed |
| 1Y | VRDN: down 17.2% S&P 500: up 15.5% | VRDN trailed the S&P 500 by 32.7 percentage points Trailed |
| Long term | ||
| 3Y | VRDN: up 60.4% S&P 500: up 75.0% +17.0% vs +20.5% a year | VRDN trailed the S&P 500 by 14.6 percentage points Trailed |
| 5Y | VRDN: up 11.6% S&P 500: up 71.2% +2.2% vs +11.4% a year | VRDN trailed the S&P 500 by 59.6 percentage points Trailed |
| 10Y | VRDN: down 82.0% S&P 500: up 258.1% −15.8% vs +13.6% a year | VRDN trailed the S&P 500 by 340.1 percentage points Trailed |
$10,000 invested in VRDN 10 years ago (Oct 14, 2016) would be worth about $1,800 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$2,045.25
Closing high on . Now 99.1% below that record.
Split-adjusted daily closes since Jun 18, 2014.
Stock splits
2
Latest: 1-for-15 on . Share counts adjust after each split.
Both splits
- 1-for-15
- 1-for-15
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $71.13Mup 23,220.3%
- Net income
- −$386.97M
- Diluted EPS
- −$3.39
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $86.00K | −$76.69M | −$0.88 |
| Q4 FY24 (Dec 31, 2024) | $72.00K | −$79.73M | −$0.81 |
| Q1 FY25 (Mar 31, 2025) | $72.00K | −$86.91M | −$0.87 |
| Q2 FY25 (Jun 30, 2025) | $75.00K | −$100.74M | −$1.00 |
| Q3 FY25 (Sep 30, 2025) | $70.57M | −$34.60M | −$0.34 |
| Q4 FY25 (Dec 31, 2025) | $132.00K | −$120.36M | −$1.10 |
| Q1 FY26 (Mar 31, 2026) | $141.00K | −$104.90M | −$0.90 |
| Q2 FY26 (Jun 30, 2026) | $284.00K | −$127.12M | −$1.05 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $2.96M | −$79.41M | −$6.66 |
| FY22 (Dec 31, 2022) | $1.77M | −$129.87M | −$2.71 |
| FY23 (Dec 31, 2023) | $314.00K | −$237.73M | −$3.91 |
| FY24 (Dec 31, 2024) | $302.00K | −$269.95M | −$3.07 |
| FY25 (Dec 31, 2025) | $70.85M | −$342.60M | −$3.32 |
Margins
- Gross 100.0%
- Operating −569.7%
- Net −544.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$335.04MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$333.34MLast 12 months
- Capital spending$1.70MLast 12 months
- −471.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $483.65MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $981.53MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$355.80MAs of Jun 30, 2026
- Net cash$625.73MAs of Jun 30, 2026
- 16.95As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.54As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −61.3%Last 12 months
Over the last 12 months, Viridian Therapeutics lost money: its net loss was 61.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −46.0%Last 12 months
Over the last 12 months, Viridian Therapeutics’s net loss was 46.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Viridian Therapeutics Inc
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug, including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED franchise, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
VRDN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VRDN stock FAQ
What is VRDN stock’s price today?
Viridian Therapeutics (VRDN) traded at $19.05 at the close on , down $0.51 (2.61%) from the previous close of $19.56. Over the past 52 weeks it has traded between $13.18 and $34.29.
If you invested $1,000 in VRDN 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in VRDN on would be worth about $180 at the close on , a total return of −82.0%. The same $1,000 would be worth $1,116 if invested five years ago and $828 if invested one year ago. Past performance doesn’t predict future returns.
What is VRDN’s P/E ratio?
VRDN’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$3.39).
How much revenue does Viridian Therapeutics make?
Viridian Therapeutics reported $71.1 million of revenue over the four quarters to , up 23,220.3% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $284.0 thousand, up 278.7% from a year earlier.
Is Viridian Therapeutics profitable?
Not over the four quarters to . Viridian Therapeutics reported a net loss of $387.0 million across those four quarters on $71.1 million of revenue.
What are VRDN’s earnings per share?
VRDN’s diluted earnings per share were −$3.39 over the four quarters to , compared with −$3.56 in the twelve months before. The latest quarter (Q2 FY26) brought −$1.05 per share, against −$1.00 a year earlier (how EPS works).
Does VRDN pay a dividend?
Viridian Therapeutics hasn’t paid a dividend in the last twelve months.
What is VRDN’s 52-week high and low?
Over the past 52 weeks VRDN has traded as low as $13.18 and as high as $34.29. At $19.05 at the close on , it is 44.4% below that high and 44.5% above the low.
What is VRDN’s all-time high?
VRDN’s highest closing price was $2,045.25 on , adjusted for stock splits. At $19.05 at the close on , it is 99.1% below that record.
Has VRDN stock ever split?
Yes, twice: 1-for-15 on ; 1-for-15 on .
How has VRDN stock performed?
Including dividends and measured to the close on , VRDN has returned −38.8% so far this year and −17.2% over the past year, and +11.6% over five years (+2.2% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Viridian Therapeutics in?
Viridian Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does VRDN trade on?
Viridian Therapeutics trades on the Nasdaq under the ticker symbol VRDN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.